© 2003 AlphaMed Press The Molecular Perspective: Protein FarnesyltransferaseCorrespondence: David S. Goodsell, Ph.D., Associate Professor, The Scripps Research Institute, Department of Molecular Biology, 10550 North Torrey Pines Road, La Jolla, California 92037, USA. Telephone: 858-784-2839; Fax: 858-784-2860; e-mail: goodsell{at}scripps.edu Website: http://www/scripps.edu/pub/goodsell
Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com
In cell signaling, a lot of the action occurs at the cell membrane. Messages arrive at the cell surface and are picked up by receptors. Then, they are processed by a collection of proteins on the inner surface of the membrane and, finally, they are dispatched to their different recipients in the cytoplasm or nucleus. Most of these proteins need ways of staying close to the membrane, where the action is, and not wandering off to other areas. Receptors are often built with large segments that cross the membrane, anchoring them permanently in place. The various signal-processing proteins on the inner surface, however, take a leaner approach. Proteins like Ras and the trimeric G proteins use small lipid molecules to anchor themselves to the inner surface of the cell membrane. These lipids are attached directly to the protein chain. Some are snaky saturated lipids, like 14-carbon myristoyl chains or 16-carbon palmitoyl chains, and some are rigidified unsaturated lipids built from isoprene units, such as 15-carbon farnesyl groups and 20-carbon geranylgeranyl groups. All of them strongly prefer the lipid environment of the membrane rather than the watery environment of the cytoplasm, so they insert into the membrane, tethering the protein in place.
The enzyme protein farnesyltransferase attaches farnesyl groups to cysteine amino acids at the ends of certain protein chains, such as that of the Ras protein (Fig. 1
The farnesyl chain in the Ras protein is essential for its normal function since Ras is intimately involved with the transfer of growth signals at the cell surface. Cancer cells with mutations in Ras also rely on this farnesyl chain to tether their hyperactive forms of the protein to the cell membrane. This makes protein farnesyltransferase an attractive target for the development of anticancer drugs. By stopping the enzyme, we can stop the production of Ras and slow the growth of cancer cells. Computer-aided drug design has been used to develop a variety of different inhibitors of the enzyme based on the atomic structure of the protein. Some mimic the protein chain, some mimic the lipid, and some are big ring-shaped molecules that fill the whole active site. Several candidates are currently being tested and are showing good prospects in clinical evaluations.
Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241269.[CrossRef][Medline] Long SB, Casey PJ, Beese LS. Reaction path of protein farnesyltransferase at atomic resolution. Nature 2002;419:645650.[CrossRef][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||